Callisto files $25 million shelf registration

By Devika Patel

Knoxville, Tenn., April 16 - Callisto Pharmaceuticals, Inc. filed a $25 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers preferred stock, common stock, warrants and units.

The preferred stock may be convertible.

Proceeds will be used for general corporate purposes.

Callisto, located in New York, develops drugs to treat cancer and gastrointestinal diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.